Aarti Pharmalabs' Q2 FY 2025-26 Quarterly Results
- 10 Nov 2025
Result Summary
- Aarti Pharmalabs Ltd reported a 7.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 9.5%.
- Its expenses for the quarter were up by 18.3% QoQ and down 3.0% YoY.
- The net profit decreased 43.6% QoQ and decreased 48.9% YoY.
- The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 3.08 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
| (₹ crores) | Q2FY26 | Q1FY26 | Q2FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 418.39 | 387.79 | 462.51 | 7.9% | -9.5% |
Total Expenses | 379.06 | 320.53 | 390.74 | 18.3% | -3.0% |
Profit Before Tax | 39.33 | 67.25 | 71.77 | -41.5% | -45.2% |
Tax | 10.77 | 15.95 | 17.15 | -32.5% | -37.2% |
Profit After Tax | 27.92 | 49.50 | 54.62 | -43.6% | -48.9% |
Earnings Per Share | 3.08 | 5.46 | 6.02 | -43.6% | -48.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aarti Pharmalabs Ltd is a company that operates within the pharmaceutical industry. It is involved in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company's portfolio likely includes active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals, which are essential components in the production of medicines and other health-related products. As of the latest available data, there are no recent major developments mentioned for Aarti Pharmalabs Ltd. However, the pharmaceutical sector is known for its dynamic nature, driven by innovation, regulatory changes, and market demands.
Revenue
During the second quarter of the fiscal year 2026 (Q2FY26), Aarti Pharmalabs Ltd reported a total income of ₹418.39 crores. This figure represents a 7.9% increase from the previous quarter (Q1FY26), which recorded a total income of ₹387.79 crores. However, when compared to the corresponding quarter of the previous year (Q2FY25), the total income shows a decrease of 9.5%, down from ₹462.51 crores. These changes in revenue highlight the variability in the company's income on both a quarterly and annual basis.
Profitability
The profitability metrics for Aarti Pharmalabs Ltd in Q2FY26 reflect a decrease compared to both the previous quarter and the same quarter in the prior year. Profit Before Tax (PBT) was reported at ₹39.33 crores, showing a decline of 41.5% from ₹67.25 crores in Q1FY26 and a 45.2% decrease from ₹71.77 crores in Q2FY25. Similarly, the Profit After Tax (PAT) for Q2FY26 was ₹27.92 crores, down by 43.6% from ₹49.50 crores in Q1FY26 and 48.9% from ₹54.62 crores in Q2FY25. The earnings per share (EPS) also decreased from 5.46 in Q1FY26 and 6.02 in Q2FY25 to 3.08 in Q2FY26, reflecting the overall decline in profitability.
Operating Metrics
The operating expenses of Aarti Pharmalabs Ltd have shown a noticeable increase in the second quarter of FY26. Total expenses amounted to ₹379.06 crores, which is an 18.3% rise from ₹320.53 crores in Q1FY26. However, when compared to the same quarter of the previous year (Q2FY25), total expenses decreased slightly by 3.0% from ₹390.74 crores. The tax expenses for Q2FY26 were ₹10.77 crores, reflecting a decrease of 32.5% from ₹15.95 crores in Q1FY26 and 37.2% from ₹17.15 crores in Q2FY25. These metrics indicate fluctuations in the company's operating expenses and tax liabilities over the analyzed periods.
FAQs
When was Aarti Pharmalabs Ltd Q2 FY 2025-26 result announced?
Aarti Pharmalabs Ltd announced its Q2 FY 2025-26 results on 10 November, 2025.
What are Aarti Pharmalabs Ltd quarterly results?
Aarti Pharmalabs Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Aarti Pharmalabs Ltd Q2 FY 2025-26 results?
Key highlights of Aarti Pharmalabs Ltd Q2 FY 2025-26 results include:
- Revenue: ₹418.39 crore
- Net Profit: ₹27.92 crore
- EBITDA: ₹74.77 crore
- Year-over-Year Growth: -9.5%
- Quarter-over-Quarter Growth: 7.9%
How did Aarti Pharmalabs Ltd net profit perform in this quarter?
Aarti Pharmalabs Ltd reported a net loss of ₹27.92 crore in Q2 FY 2025-26, reflecting a -48.9% year-over-year growth.
What was Aarti Pharmalabs Ltd revenue in Q2 FY 2025-26?
Aarti Pharmalabs Ltd posted a revenue of ₹418.39 crore in Q2 FY 2025-26.